Stock Research: Fulcrum Therapeutics

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Fulcrum Therapeutics

NasdaqGM:FULC US3596161097
49
  • Value
    58
  • Growth
    88
  • Safety
    Safety
    65
  • Combined
    54
  • Sentiment
    54
  • 360° View
    360° View
    49
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecules for genetically defined rare diseases. It operates in the biopharmaceutical industry, focusing on therapies for conditions like sickle cell disease and inherited aplastic anemias (Diamond-Blackfan anemia, Shwachman-Diamond syndrome, and Fanconi anemia). In the last fiscal year, the company had 45 employees, a market cap of $425 million, $0 profits, and $80 million in revenue.

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 18-Dec-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
58 63 29 39
Growth
88 19 97 19
Safety
Safety
65 65 79 79
Sentiment
54 10 54 59
360° View
360° View
49 49 17 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
57 1 39 47
Opinions Change
50 50 72 50
Pro Holdings
n/a 25 54 73
Market Pulse
33 32 41 42
Sentiment
54 10 54 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
58 63 29 39
Growth
88 19 97 19
Safety Safety
65 65 79 79
Combined
54 54 82 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
18 18 18 18
Price vs. Earnings (P/E)
48 54 3 11
Price vs. Book (P/B)
49 73 62 54
Dividend Yield
1 1 1 1
Value
58 63 29 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
100 8 81 13
Profit Growth
1 89 60 37
Capital Growth
100 27 99 15
Stock Returns
94 17 61 83
Growth
88 19 97 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 100 100 73
Refinancing
72 92 83 81
Liquidity
1 1 6 6
Safety Safety
65 65 79 79

Similar Stocks

Discover high‑ranked alternatives to Fulcrum Therapeutics and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

This is an all-around strong stock. It shows good value, high growth, safe financing, and positive professional sentiment. It is ideal for most buy-and-hold investors who value a good all-around stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: